Hyaluronidase expression induces prostate tumor metastasis in an orthotopic mouse model

American Journal of Pathology

Volumn 169, Issue 4, 2006, Pages 1415-1426

  Kovar, Joy L ^a   Johnson, Mark A ^a   Volcheck, William M ^a   Chen, Jiyan ^a   Simpson, Melanie A ^b  

^a LI COR BIOSCIENCES   (United States)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYE; EPIDERMAL GROWTH FACTOR RECEPTOR; HYALURONIDASE; EPIDERMAL GROWTH FACTOR; HYALURONOGLUCOSAMINIDASE; INDOLE DERIVATIVE; IRDYE800;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CLEARANCE; HUMAN; HUMAN CELL; IMAGING SYSTEM; IN VITRO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; CANCER TRANSPLANTATION; DISEASE MODEL; ENZYMOLOGY; GENETICS; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; EPIDERMAL GROWTH FACTOR; HUMANS; HYALURONOGLUCOSAMINIDASE; INDOLES; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MICE; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS;

EID: 33845877573     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.060324     Document Type: Article

References (50)

1. Hughes C, Murphy A, Martin C, Sheils O, O'Leary J: Molecular pathology of prostate cancer. J Clin Pathol 2005, 58:673-684
2. Pienta KJ, Smith DC: Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 2005, 55:300-323
3. Cher ML: Mechanisms governing bone metastasis in prostate cancer. Curr Opin Urol 2001, 11:483-488
4. Ekici S, Cerwinka WH, Duncan R, Gomez P, Civantos F, Soloway MS, Lokeshwar VB: Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int J Cancer 2004, 112:121-129
5. Lokeshwar VB, Cerwinka WH, Isoyama T, Lokeshwar BL: HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res 2005, 65:7782-7789
6. Lokeshwar VB, Lokeshwar BL, Pham HT, Block NL: Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate cancer progression. Cancer Res 1996, 56:651-657
7. Lokeshwar VB, Rubinowicz D, Schroeder GL, Forgacs E, Minna JD, Block NL, Nadji M, Lokeshwar BL: Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem 2001, 276:11922-11932
8. Posey JT, Soloway MS, Ekici S, Sofer M, Civantos F, Duncan RC, Lokeshwar VB: Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. Cancer Res 2003, 63:2638-2644
9. Rembrink K, Romijn JC, van der Kwast TH, Rubben H, Schroder FH: Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer. Prostate 1997, 31:168-174
10. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ: Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 1996, 2:1627-1636
11. Sramkoski RM, Pretlow II TG, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW: A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999, 35:403-409
12. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS: Molecular characterization of human prostate carcinoma cell lines. Prostate 2003, 57:205-225
13. Frangioni JV: In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol 2003, 7:626-634
14. Gurfinkel M, Ke S, Wen X, Li C, Sevick-Muraca EM: Near-infrared fluorescence optical imaging and tomography. Dis Markers 2003, 19:107-121
15. Ntziachristos V, Bremer C, Weissleder R: Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol 2003, 13:195-208
16. Ntziachristos V, Ripoll J, Wang LV, Weissleder R: Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol 2005, 23:313-320
17. Weissleder R: A clearer vision for in vivo imaging. Nature Biotechnol 2001, 19:316-317
18. Weissleder R: Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer 2002, 2:11-18
19. Weissleder R, Ntziachristos V: Shedding light onto live molecular targets. Nat Med 2003, 9:123-128
20. Jobsis FF: Noninvasive, infrared monitoring of cerebral and myocardial oxygen sufficiency and circulatory parameters. Science 1977, 198:1264-1267
21. Chance B: Optical method. Annu Rev Biophys Biophys Chem 1991, 20:1-28
22. Citrin D, Lee AK, Scott T, Sproull M, Menard C, Tofilon PJ, Camphausen K: In vivo tumor imaging in mice with near-infrared labeled endostatin. Mol Cancer Ther 2004, 3:481-488
23. Ke S, Wen X, Gurfinkel M, Charnsangavej C, Wallace S, Sevick-Muraca EM, Li C: Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res 2003, 63:7870-7875
24. Becker A, Hessenius C, Licha K, Ebert B, Sukowski U, Semmler W, Wiedenmann B, Grotzinger C: Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol 2001, 19:327-331
25. Aina OH, Marik J, Gandour-Edwards R, Lam KS: Near-infrared optical imaging of ovarian cancer xenografts with novel alpha3-integrin binding peptide "OA02." Mol Imaging 2005, 4:439-447
26. Chen X, Conti PS, Moats RA: In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res 2004, 64:8009-8014
27. Cheng Z, Wu Y, Xiong Z, Gambhir SS, Chen X: Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjug Chem 2005, 16:1433-1441
28. Houston JP, Ke S, Wang W, Li C, Sevick-Muraca EM: Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe. J Biomed Opt 2005, 10:054010
29. Wang W, Ke S, Wu Q, Charnsangavej C, Gurfinkel M, Gelovani JG, Abbruzzese JL, Sevick-Muraca EM, Li C: Near-infrared optical imaging of integrin alphavbeta3 in human tumor xenografts. Mol Imaging 2004, 3:343-351
30. Kraus MH, Popescu NC, Amsbaugh SC, King CR: Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 1987, 6:605-610
31. Levitzki A: EGF receptor as a therapeutic target. Lung Cancer 2003, 41(Suppl 1):S9-S14
32. Maihle NJ, Baron AT, Barrette BA, Boardman CH, Christensen TA, Cora EM, Faupel-Badger JM, Greenwood T, Juneja SC, Lafky JM, Lee H, Reiter JL, Podratz KC: EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res 2002, 107:247-258
33. Kyritsis AP, Saya H: Epidemiology, cytogenetics, and molecular biology of brain tumors. Curr Opin Oncol 1993, 5:474-480
34. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F: Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002, 8:3438-3444
35. Simpson MA: Concurrent expression of hyaluronan biosynthetic and processing enzymes promotes growth and vascularization of prostate tumors in mice. Am J Pathol 2006, 169:247-257
36. Chen H, Kovar J, Sissons S, Cox K, Matter W, Chadwell F, Luan P, Vlahos CJ, Schutz-Geschwender A, Olive DM: A cell-based immunocytochemical assay for monitoring kinase signaling pathways and drug efficacy. Anal Biochem 2005, 338:136-142
37. Simpson MA, Wilson CM, McCarthy JB: Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am J Pathol 2002, 161:849-857
38. Harding J, Burtness B: Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody. Drugs Today (Barc) 2005, 41:107-127
39. Patel S, Turner PR, Stubberfield C, Barry E, Rohlff CR, Stamps A, McKenzie E, Young K, Tyson K, Terrett J, Box G, Eccles S, Page MJ: Hyaluronidase gene profiling and role of hyal-1 overexpression in an orthotopic model of prostate cancer. Int J Cancer 2002, 97:416-424
40. Csoka AB, Frost GI, Stern R: The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol 2001, 20:499-508
41. Lin G, Stern R: Plasma hyaluronidase (Hyal-1) promotes tumor cell cycling. Cancer Lett 2001, 163:95-101
42. Liu D, Pearlman E, Diaconu E, Guo K, Mori H, Haqqi T, Markowitz S, Willson J, Sy MS: Expression of hyaluronidase by tumor cells induces angiogenesis in vivo. Proc Natl Acad Sci USA 1996, 93:7832-7837
43. Stern R: Hyaluronan catabolism: a new metabolic pathway. Eur J Cell Biol 2004, 83:317-325
44. West DC, Hampson IN, Arnold F, Kumar S: Angiogenesis induced by degradation products of hyaluronic acid. Science 1985, 228:1324-1326
45. Mullegger J, Lepperdinger G: Degradation of hyaluronan by a Hyal2-type hyaluronidase affects pattern formation of vitelline vessels during embryogenesis of Xenopus laevis. Mech Dev 2002, 111:25-35
46. Ghatak S, Misra S, Toole BP: Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem 2002, 277:38013-38020
47. Toole BP: Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004, 4:528-539
48. Carraway III KL, Cerione RA: Fluorescent-labeled growth factor molecules serve as probes for receptor binding and endocytosis. Biochemistry 1993, 32:12039-12045
49. Lidke DS, Nagy P, Heintzmann R, Arndt-Jovin DJ, Post JN, Grecco HE, Jares-Erijman EA, Jovin TM: Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nat Biotechnol 2004, 22:198-203
50. Zacharakis G, Kambara H, Shih H, Ripoll J, Grimm J, Saeki Y, Weissleder R, Ntziachristos V: Volumetric tomography of fluorescent proteins through small animals in vivo. Proc Natl Acad Sci USA 2005, 102:18252-18257